{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:48Z","timestamp":1787021268776,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1208\/s12249-019-1489-6","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T15:02:13Z","timestamp":1564671733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation"],"prefix":"10.1208","volume":"20","author":[{"given":"Hemant","family":"Bhalerao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. B.","family":"Koteshwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajeev","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"issue":"11","key":"1489_CR1","first-page":"38","volume":"3","author":"S Sonawane","year":"2014","unstructured":"Sonawane S, Lahoti S. Design and evaluation of ion induced in situ gel formulation for levofloxacin hemihydrate ocular delivery. Int J Pharm Sci Invent. 2014;3(11):38\u201343.","journal-title":"Int J Pharm Sci Invent"},{"issue":"7","key":"1489_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3109\/10717544.2013.838712","volume":"20","author":"H Gupta","year":"2013","unstructured":"Gupta H, Aquil M, Khar R, Ali A. Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention. Drug Deliv. 2013;20(7):306\u20139. \n                    https:\/\/doi.org\/10.3109\/10717544.2013.838712\n                    \n                  .","journal-title":"Drug Deliv"},{"issue":"3","key":"1489_CR3","first-page":"608","volume":"2","author":"P Sapra","year":"2013","unstructured":"Sapra P, Patel D, Soniwala M, Chavda J. Development and optimization of in situ periodental gel containing levofloxacin for the treatment of periodontal disease. J Sci Innov Res. 2013;2(3):608\u201327.","journal-title":"J Sci Innov Res"},{"issue":"1","key":"1489_CR4","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1167\/iovs.12-9695","volume":"54","author":"T Want","year":"2013","unstructured":"Want T, Huang X, Gao Q, Feng L, Xie Z, Jiang Z, et al. A preliminary study to treat severe endophthalmitis via a foldable capsular vitreous body with sustained levofloxacin release in rabbits. Invest Ophthalmol Vis Sci. 2013;54(1):804\u201312. \n                    https:\/\/doi.org\/10.1167\/iovs.12-9695\n                    \n                  .","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1489_CR5","first-page":"655","volume":"4","author":"N Mahesh","year":"2012","unstructured":"Mahesh N, Manjula B. Study of an alginate\/HPMC based in-situ gelling ophthalmic delivery system for levofloxacin hydrochloride. Int J Pharm Pharm Sci. 2012;4(3):655\u20138.","journal-title":"Int J Pharm Pharm Sci"},{"issue":"6","key":"1489_CR6","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1002\/jps.23087","volume":"101","author":"G Kumar","year":"2012","unstructured":"Kumar G, Sharma S, Malhotra S. Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. J Pharm Sci. 2012;101(6):2165\u201376. \n                    https:\/\/doi.org\/10.1002\/jps.23087\n                    \n                  .","journal-title":"J Pharm Sci"},{"issue":"1","key":"1489_CR7","first-page":"24","volume":"1","author":"H Gevariya","year":"2009","unstructured":"Gevariya H, Patel J, Girhepunje K, Pal R. Sustained ophthalmic delivery of levofloxacin from once a day Ocuserts. Int J Pharm Pharm Sci. 2009;1(1):24\u201332.","journal-title":"Int J Pharm Pharm Sci"},{"key":"1489_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejpb.2004.12.007","volume":"60","author":"K Hosoya","year":"2005","unstructured":"Hosoya K, Lee V, Kim K. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanism and their regulation. Eur J Pharm Biopharm. 2005;60:227-40. \n                    https:\/\/doi.org\/10.1016\/j.ejpb.2004.12.007\n                    \n                  .","journal-title":"Eur J Pharm Biopharm"},{"key":"1489_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajps.2018.04.008","volume":"2018","author":"W Yumei","year":"2019","unstructured":"Yumei W, Liu Y, Li X, Kebebe D, Zhang B, Ren J, et al. Research progress of in-situ gelling ophthalmic drug delivery system. Asian J Pharm Sci. 2019;2018:1\u201315. \n                    https:\/\/doi.org\/10.1016\/j.ajps.2018.04.008\n                    \n                  .","journal-title":"Asian J Pharm Sci"},{"issue":"2","key":"1489_CR10","first-page":"1398","volume":"2","author":"H Nirmal","year":"2010","unstructured":"Nirmal H, Bakliwal S, Pawar S. In-situ gel: new trends in controlled and sustained drug delivery system. Int J PharTech Res. 2010;2(2):1398\u2013408.","journal-title":"Int J PharTech Res"},{"key":"1489_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.heliyon.2017.e00390","volume":"3","author":"A Fakhari","year":"2017","unstructured":"Fakhari A, Corcoran M, Schwarz A. Thermogelling properties of purified poloxamer 407. Heliyon. 2017;3:1\u201326. \n                    https:\/\/doi.org\/10.1016\/j.heliyon.2017.e00390\n                    \n                  .","journal-title":"Heliyon"},{"issue":"8","key":"1489_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1590\/S0100-40422013000800008","volume":"36","author":"G Pereira","year":"2013","unstructured":"Pereira G, Dimer F, Guterres S. Formulation and characterization of Poloxamer 407\u00ae: thermoreversisble gel containing polymeric microparticles and hyaluronic acid. Quim Nova. 2013;36(8):1121\u20135.","journal-title":"Quim Nova"},{"key":"1489_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijpharm.2007.09.005","volume":"350","author":"M Wen-Di","year":"2007","unstructured":"Wen-Di M, Wang C, Nie S, Pan W. Pluronuc F127-g-poly (acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int J Pharm. 2007;350:247\u201356. \n                    https:\/\/doi.org\/10.1016\/j.ijpharm.2007.09.005\n                    \n                  .","journal-title":"Int J Pharm"},{"key":"1489_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0928-0987(97)00075-4","volume":"6","author":"K Edsman","year":"1998","unstructured":"Edsman K, Carfors J, Petersson R. Rheological evaluation of polxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci. 1998;6:105\u201312.","journal-title":"Eur J Pharm Sci"},{"key":"1489_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0168-3659(01)00279-6","volume":"73","author":"B Srividya","year":"2001","unstructured":"Srividya B, Cardoza R, Amin P. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release. 2001;73:205\u201311.","journal-title":"J Control Release"},{"issue":"1-2","key":"1489_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijpharm.2011.03.007","volume":"410","author":"Haoyun Wu","year":"2011","unstructured":"Wu H, Liu Z, Peng J, Li L, Li N, Li J, et al. Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery. Int J Pharm. 2011;410:31\u201340. \n                    https:\/\/doi.org\/10.1016\/j.ijpharm.2011.03.007\n                    \n                  .","journal-title":"International Journal of Pharmaceutics"},{"issue":"2","key":"1489_CR17","first-page":"452","volume":"4","author":"N Shashank","year":"2012","unstructured":"Shashank N, Sogali B, Thakur R. Formulation and evaluation of pH triggered in situ ophthalmic gel of moxifloxacin hydrochloride. Int J Pharm Pharm Sci. 2012;4(2):452\u20139.","journal-title":"Int J Pharm Pharm Sci"},{"key":"1489_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1533\/9781845698331.22","volume-title":"Food polymers, gels, and colloids","author":"G Robinson","year":"1991","unstructured":"Robinson G, Manning CE, Morris ER. Conformation and physical properties of the bacterial polysaccharides gellan, welan and rhamsan. In: Dickinson E, editor. Food polymers, gels, and colloids. London: The Royal Society Chemistry; 1991. p. 22."},{"key":"1489_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4028\/www.scientific.net\/AMM.284-287.20","volume":"284-287","author":"Y Meng","year":"2013","unstructured":"Meng Y, Hong L, Jin J. A study on the gelation properties and rheological behavior of Gellan gum. Appl Mech Mater. 2013;284-287:20\u20134. \n                    https:\/\/doi.org\/10.4028\/www.scientific.net\/AMM.284-287.20\n                    \n                  .","journal-title":"Appl Mech Mater"},{"issue":"1-2","key":"1489_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijpharm.2011.03.042","volume":"411","author":"Ilva D. Rupenthal","year":"2011","unstructured":"Rupenthal I, Green C, Alany R. Comparision of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterization and in vitro release. Int J Pharm 2011;411:469\u201377. \n                    https:\/\/doi.org\/10.1016\/j.ijpharm.2011.03.042\n                    \n                  , 69.","journal-title":"International Journal of Pharmaceutics"},{"issue":"2","key":"1489_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/2230-973X.100042","volume":"2","author":"S Mandal","year":"2012","unstructured":"Mandal S, Thimmasetty M, Prabhushankar G, Geetha M. Formulation and evaluation of an in situ gel forming ophthalmic formulation of moxifloxacin hydrochloride. Int J Pharm Investig. 2012;2(2):78\u201382.","journal-title":"Int J Pharm Investig"},{"issue":"2","key":"1489_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0172306","volume":"12","author":"U Kotreka","year":"2017","unstructured":"Kotreka U, Davis V, Adeyeye M. Development of topical ophthalmic in situ gel-forming estradiol delivery system intended for the pevention of age-related cataracts. PLoS One. 2017;12(2):1\u201319. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0172306\n                    \n                  .","journal-title":"PLoS One"},{"issue":"3","key":"1489_CR23","first-page":"296","volume":"3","author":"S Somasundaram","year":"2013","unstructured":"Somasundaram S, Manivannan K. An overview of fluoroquinolones. Ann Rev Res Biol. 2013;3(3):296\u2013313.","journal-title":"Ann Rev Res Biol"},{"issue":"7","key":"1489_CR24","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/ICO.0b013e31828d6d9e","volume":"32","author":"J Chung","year":"2013","unstructured":"Chung J, Lim E, Song S, Kim B, Lee J, Mah F, et al. Comparative intraocular penetration of 4 fluoroquinolones after topical instillation. Cornea. 2013;32(7):1046\u201351.","journal-title":"Cornea."},{"issue":"6","key":"1489_CR25","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1128\/AAC.48.6.1948-1952.2004","volume":"48","author":"J. J. Dajcs","year":"2004","unstructured":"Dajcs J, Thibodeaux B, Marquart M, Girgis D, traidej M, O\u2019Callaghan R. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Animicrobial Agents Chemother. 2004;48(6):1948\u201352. \n                    https:\/\/doi.org\/10.1128\/AAC.48.6.1948-1952.2004\n                    \n                  .","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"1489_CR26","first-page":"301","volume":"22","author":"A Shirkhedkar","year":"2009","unstructured":"Shirkhedkar A. Quantitative determination of levofloxacin hemihydrate in bulk and tablets by UV-spectrophotometry and first order derivative methods. Pak J Pharm Sci. 2009;22(3):301\u20132.","journal-title":"Pak J Pharm Sci"},{"key":"1489_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/chromsci\/48.6.484","volume":"48","author":"H Gupta","year":"2010","unstructured":"Gupta H, Aquil M, Khar R, Ali A, Chander P. A single reversed-phase UPLC method for quantification of levofloxacin in aqueous humor and pharmaceutical dosage forms. J Chromatogr Sci. 2010;48:484\u201390. \n                    https:\/\/doi.org\/10.1093\/chromsci\/48.6.484\n                    \n                  .","journal-title":"J Chromatogr Sci"},{"key":"1489_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IJN.S25268","volume":"7","author":"Z Jiang","year":"2012","unstructured":"Jiang Z, Want T, Pan B, Xie Z, Wang P, Liu Y, et al. Evaluation of the levofloxacin release characters from a rabbit foldable capsular vitreous body. Int J Nanomedicine. 2012;7:1\u201310. \n                    https:\/\/doi.org\/10.2147\/IJN.S25268\n                    \n                  .","journal-title":"Int J Nanomedicine"},{"issue":"5","key":"1489_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1076\/ceyr.24.5.403.8517","volume":"24","author":"M Yamada","year":"2002","unstructured":"Yamada M, Mochizuki H, Yamada K, Kawai M, Mashima Y. Aqueous humor levels of topically applied levolfloxacin in human eyes. Curr Eye Res. 2002;24(5):403\u20136.","journal-title":"Curr Eye Res"},{"key":"1489_CR30","unstructured":"OECD guidaline for testing of chemical, acute eye irritation\/corrosion 405: 2017. \n                    https:\/\/www.oecd.org\/env\/test-no-405-acute-eye-irritation-corrosion-9789264185333-en.htm\n                    \n                  . Accessed 6 July 2019"},{"key":"1489_CR31","unstructured":"ICH. International Conference on Harmonization (ICH) of Technical requirements for Registration of Pharmaceuticals for Human Use. Harmonized triplicate guideline on stability testing of new drug substances and products Q1A (R2), approved for adoption at step 4 of ICH process on February 2003 by ICH steering committee. \n                    https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q1A_R2\/Step4\/Q1A_R2_Guideline.pdf \n                    \n                  . Accessed 6 July 2019"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1489-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-019-1489-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1489-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T19:07:16Z","timestamp":1596136036000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-019-1489-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1208\/s12249-019-1489-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]},"assertion":[{"value":"28 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal handling and studies were conducted in accordance with the Principles of Laboratory Animal Care (National Institutes of Health publication no 92\u201393, revised in 1985) and in conformation with guidelines of The Association for Research in Vision and Ophthalmology. The Institutional Animal Ethics Committee of Poona College of Pharmacy, Pune, India, approved the study (Protocol no: CPCSEA\/PCP\/PCL01\/2018 and CPCSEA\/PCP\/PCL27\/2018).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"272"}}